Filgrastim Recruiting Phase 2 Trials for Recurrent Burkitt Lymphoma / Acute Lymphoblastic Leukaemia Recurrent / Burkitt Leukemia/Lymphoma / Refractory Burkitt Leukemia / Lymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory / Hematopoietic/Lymphoid Cancer / Recurrent Adult Lymphoblastic Lymphoma / Lymphoma, Lymphoblastic / Recurrent Childhood Lymphoblastic Lymphoma / Acute Lymphoblastic Leukaemias (ALL) / Burkitt's Lymphoma / High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / Refractory Burkitt Lymphoma / Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / Recurrent Burkitt Leukemia / Refractory Acute Lymphoblastic Leukemia Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03136146Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
NCT03318419Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia